[go: up one dir, main page]

FR14C0055I1 - - Google Patents

Info

Publication number
FR14C0055I1
FR14C0055I1 FR14C0055C FR14C0055I1 FR 14C0055 I1 FR14C0055 I1 FR 14C0055I1 FR 14C0055 C FR14C0055 C FR 14C0055C FR 14C0055 I1 FR14C0055 I1 FR 14C0055I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22585009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0055(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0055I1 publication Critical patent/FR14C0055I1/fr
Application granted granted Critical
Publication of FR14C0055I2 publication Critical patent/FR14C0055I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR14C0055C 1998-09-29 2014-07-21 SUBSTITUTED CYANOQUINOLINES 3 AS PROTEIN TYROSINE KINASE INHIBITORS Active FR14C0055I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16228998A 1998-09-29 1998-09-29
EP99948411A EP1117649A1 (en) 1998-09-29 1999-09-22 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
EP20080002592 EP1950201A1 (en) 1998-09-29 1999-09-22 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

Publications (2)

Publication Number Publication Date
FR14C0055I1 true FR14C0055I1 (en) 2014-08-22
FR14C0055I2 FR14C0055I2 (en) 2016-06-10

Family

ID=22585009

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0055C Active FR14C0055I2 (en) 1998-09-29 2014-07-21 SUBSTITUTED CYANOQUINOLINES 3 AS PROTEIN TYROSINE KINASE INHIBITORS

Country Status (28)

Country Link
EP (4) EP1950201A1 (en)
JP (1) JP4537582B2 (en)
KR (1) KR100736502B1 (en)
CN (1) CN1144786C (en)
AR (1) AR035002A1 (en)
AU (1) AU6159499A (en)
BE (1) BE2014C048I2 (en)
BR (2) BR9914164A (en)
CA (1) CA2344168C (en)
CY (2) CY1115124T1 (en)
CZ (1) CZ303681B6 (en)
DK (1) DK2253620T3 (en)
EA (1) EA004427B1 (en)
ES (1) ES2457396T3 (en)
FR (1) FR14C0055I2 (en)
HK (1) HK1208456A1 (en)
HU (2) HU230728B1 (en)
IL (2) IL142092A0 (en)
LT (1) LTPA2014028I1 (en)
LU (1) LU92428I2 (en)
NO (1) NO20011574L (en)
NZ (1) NZ510580A (en)
PL (1) PL218769B1 (en)
PT (1) PT2253620E (en)
SI (1) SI2253620T1 (en)
SK (1) SK287767B6 (en)
WO (1) WO2000018740A1 (en)
ZA (1) ZA200102501B (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29800A (en) * 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma 4-AMINO-KINAZOLIN AND KINOLIN DISTRICTS THAT HAVE INHIBITOR EFFECTS ON SIGNAL TRANSDUKSI MEDIUMED BY THYROSIN KINASE
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
AR035851A1 (en) * 2000-03-28 2004-07-21 Wyeth Corp 3-CIANOQUINOLINS, 3-CIANO-1,6-NAFTIRIDINES AND 3-CIANO-1,7-NAFTIRIDINS AS INHIBITORS OF PROTEIN KINASES
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
ES2280375T3 (en) * 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG BICYCLE HETEROCICLES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURE FOR PREPARATION.
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6740651B2 (en) 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
WO2003000705A1 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
MXPA04004969A (en) 2001-11-27 2004-08-11 Wyeth Corp 3-cyanoquinolines as inhibitors of egf-r and her2 kinases.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE10217689A1 (en) * 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CL2003002287A1 (en) * 2002-11-25 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
GEP20084357B (en) 2002-12-20 2008-04-29 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004069827A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab Quinoline derivatives and use thereof as antitumor agents
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA80607C2 (en) * 2003-04-09 2007-10-10 White Holdings Corp Process for the preparation of 3-cyano-6-alkoxy-7-nitro-4-quinolines
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
CN1984660B (en) 2003-07-03 2010-12-15 美瑞德生物工程公司 4-Arylamino-quinazolines as caspase-specific activators and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
ES2305844T3 (en) 2003-09-16 2008-11-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINE AS INHIBITORS OF THYROSINE KINASE.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7432377B2 (en) 2004-01-16 2008-10-07 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
ES2315834T3 (en) 2004-02-03 2009-04-01 Astrazeneca Ab DERIVATIVES OF QUINAZOLINA.
NZ588139A (en) 2004-04-08 2012-02-24 Targegen Inc 7-Aryl-3-arylamino-benzo[1,2,4]triazine derivatives
SI1746999T1 (en) 2004-05-06 2012-01-31 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
MXPA06013165A (en) 2004-05-14 2007-02-13 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
CA2566332A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
DE602006018331D1 (en) 2005-09-20 2010-12-30 Astrazeneca Ab 4- (1H-INDAZOL-5-YLAMINO) CHINAZOLINE COMPOUNDS AS INHIBITORS OF ERBB RECEPTORT ROSINKINASE FOR THE TREATMENT OF CANCER
KR101467723B1 (en) 2005-11-01 2014-12-03 탈자진 인코포레이티드 Bi-aryl meta-pyrimidine inhibitors of kinases
CA2833706C (en) 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
PL2010496T3 (en) * 2006-04-14 2011-01-31 Astrazeneca Ab 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors
RU2492864C2 (en) 2006-09-18 2013-09-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of treating cancer carrying egfr mutations
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
EP1921070A1 (en) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
BRPI0907916A2 (en) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Spirocycle heterocycles, medicaments containing such compounds, and processes for preparing them
WO2009138781A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101638383B (en) * 2008-07-29 2013-07-10 北大方正集团有限公司 Quinoline as well as pharmaceutical composition and use thereof
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
LT2451445T (en) 2009-07-06 2019-06-25 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5859118B2 (en) * 2011-05-26 2016-02-10 山東軒竹医薬科技有限公司 Quinazoline derivatives as tyrosine kinase inhibitors, their preparation and use
CN202470348U (en) * 2012-02-29 2012-10-03 珠海格力电器股份有限公司 Air deflector driving device and air conditioner indoor unit using same
CN103987700B (en) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-quinazoline amine derivant and application thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
MX389591B (en) 2014-08-29 2025-03-20 Tes Pharma S R L Inhibitors of î±-amino-î²-carboxymuconic acid semialdehyde decarboxylase
PL3896064T3 (en) * 2015-07-06 2025-09-08 Gilead Sciences, Inc. 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS COT MODULATORS IN THE TREATMENT OF CROOHN'S DISEASE AND ULTRASPECTRUM COLITIS
WO2019170543A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
TWI770527B (en) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot modulators and methods of use thereof
CN110540534B (en) * 2019-10-24 2020-11-13 枣庄学院 A kind of synthetic method of organic intermediate compound
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4613745A3 (en) 2020-04-02 2025-11-26 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470186A (en) 1967-06-02 1969-09-30 American Cyanamid Co Substituted 4-anilino-3-quinolinecarboxylic acids and esters
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
GB8804443D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU686843B2 (en) 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP0682027B1 (en) 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidine derivatives with antiproliferative action
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
CA2260058A1 (en) * 1996-07-13 1998-01-22 Kathryn Jane Smith Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PT912559E (en) 1996-07-13 2003-03-31 Glaxo Group Ltd HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0929526B1 (en) 1996-09-25 2005-07-27 AstraZeneca AB Qinoline derivatives inhibiting the effect of growth factors such as vegf
UA73073C2 (en) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives

Also Published As

Publication number Publication date
HUP0103633A3 (en) 2003-01-28
NO20011574L (en) 2001-05-28
HUP0103633A2 (en) 2002-02-28
HU230728B1 (en) 2017-12-28
EA004427B1 (en) 2004-04-29
JP2002525359A (en) 2002-08-13
AR035002A1 (en) 2004-04-14
PT2253620E (en) 2014-04-15
KR20010085856A (en) 2001-09-07
EP2896612A1 (en) 2015-07-22
BRPI9914164B8 (en) 2021-05-25
HUS1700048I1 (en) 2017-12-28
WO2000018740A1 (en) 2000-04-06
AU6159499A (en) 2000-04-17
CA2344168C (en) 2011-04-05
EP2253620A1 (en) 2010-11-24
CZ2001957A3 (en) 2001-09-12
FR14C0055I2 (en) 2016-06-10
BR9914164A (en) 2001-06-26
CZ303681B6 (en) 2013-03-06
EP1950201A1 (en) 2008-07-30
SI2253620T1 (en) 2014-06-30
HK1208456A1 (en) 2016-03-04
KR100736502B1 (en) 2007-07-06
LU92428I2 (en) 2014-06-10
CN1320118A (en) 2001-10-31
CA2344168A1 (en) 2000-04-06
SK3892001A3 (en) 2001-12-03
JP4537582B2 (en) 2010-09-01
PL346972A1 (en) 2002-03-11
PL218769B1 (en) 2015-01-30
LTPA2014028I1 (en) 2014-08-25
BE2014C048I2 (en) 2019-03-05
IL142092A (en) 2007-07-04
BRPI9914164B1 (en) 2019-02-19
CY2014034I1 (en) 2016-04-13
EP1117649A1 (en) 2001-07-25
CN1144786C (en) 2004-04-07
CY1115124T1 (en) 2016-04-13
SK287767B6 (en) 2011-09-05
DK2253620T3 (en) 2014-03-31
CY2014034I2 (en) 2016-04-13
ZA200102501B (en) 2002-01-05
IL142092A0 (en) 2002-03-10
EA200100412A1 (en) 2001-10-22
NZ510580A (en) 2003-03-28
EP2253620B1 (en) 2014-03-12
NO20011574D0 (en) 2001-03-28
ES2457396T3 (en) 2014-04-25

Similar Documents

Publication Publication Date Title
BE2014C048I2 (en)
BE2012C041I2 (en)
JP2002509389A5 (en)
BRPI9917862A2 (en)
BRPI9914151B8 (en)
JP2001524623A5 (en)
JP2001522124A5 (en)
JP2001509459A5 (en)
JP2002538057A5 (en)
IN189025B (en)
FR2760689A3 (en)
JP2558391C (en)
JP2616340C (en)
JP2558251C (en)
JP2622046C (en)
JP2556624C (en)
JP2556437C (en)
JP2555096C (en)
JP2541712C (en)
JP2587905C (en)
JP2597245C (en)
CN3074052S (en)
CN3071793S (en)
CN3073771S (en)
CN3073425S (en)